Ger­man ra­dio­phar­ma biotech ac­quires British start­up in tiny deal

Two pri­vate biotechs pulled off a small merg­er on Thurs­day.

Berlin-based Ariceum Ther­a­peu­tics ac­quired the UK’s Ther­ag­nos­tics, the com­pa­nies an­nounced, for $2.5 mil­lion up­front in cash. Per the deal, Ariceum will get 100% of Ther­ag­nos­tics shares and be on the hook for up to $41.5 mil­lion in ad­di­tion­al mile­stones.

Ariceum CEO Man­fred Rüdi­ger said in a state­ment that the deal ad­vances the com­pa­ny’s goal of “build­ing and ad­vanc­ing” a pipeline port­fo­lio, in ad­di­tion to bring­ing an FDA-ap­proved di­ag­nos­tic in­to the fold. Greg Mullen, for­mer Ther­ag­nos­tics CEO, is now Ariceum’s COO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER